

References

1. McFaline-Figueroa JR, Lee EQ. Brain Tumors. *Am J Med*. 2018 Aug 1;131(8):874–82.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.
3. Mayfield Brain & Spine, Neurosurgery, Spine surgeons, Brain surgeons, Cincinnati, Ohio [Internet]. [cited 2020 Apr 26]. Available from: <https://mayfieldclinic.com/index.htm>
4. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. *Neuro-Oncol*. 1999;1(1):14–25.
5. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. *Neuro-Oncol*. 2001;3(3):141–51.
6. Gunel JM, Piepmeier JM, Baehring J, editors. *Malignant Brain Tumors : State-of-the-Art Treatment* [Internet]. Springer International Publishing; 2017 [cited 2020 Jun 10]. Available from: <https://www.springer.com/gp/book/9783319498638>
7. Han L, Kong DK, Zheng M, Murikinati S, Ma C, Yuan P, et al. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. *ACS Nano*. 2016 Apr 26;10(4):4209–18.
8. Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin J-F, Dehoux M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. *Neoplasia N Y N*. 2008 Dec;10(12):1383–92.
9. Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. *Acta Pharm Sin B*. 2014 Jun;4(3):193–201.
10. Warren KE. Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma. *Front Oncol* [Internet]. 2018 [cited 2020 Jun 10];8. Available from: <https://www.frontiersin.org/articles/10.3389/fonc.2018.00239/full>
11. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. *Angew Chem Int Ed Engl*. 2014 Nov 10;53(46):12320–64.
12. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. *Annu Rev Med*. 2012;63:185–98.
13. Pillai G. Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. *SOJ Pharm Pharm Sci* [Internet]. 2014 Jun 27 [cited 2020

References

Jun 10];1(2). Available from: <https://symbiosisonlinepublishing.com/pharmacy-pharmaceuticalsciences/pharmacy-pharmaceuticalsciences09.php>

14. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov*. 2008 Sep;7(9):771–82.

15. Yu X, Jin C. Application of albumin-based nanoparticles in the management of cancer. *J Mater Sci Mater Med*. 2016 Jan;27(1):4.

16. Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. *Expert Opin Drug Deliv*. 2013 Oct 1;10(10):1429–48.

17. Dhas NL, Ige PP, Kudarha RR. Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer. *Powder Technol*. 2015 Oct 1;283:234–45.

18. Kumar P, Srivastava R. IR 820 stabilized multifunctional polycaprolactone glycol chitosan composite nanoparticles for cancer therapy. *RSC Adv*. 2015 Jun 23;5(69):56162–70.

19. Yang N, Jiang Y, Zhang H, Sun B, Hou C, Zheng J, et al. Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis. *Mol Pharm*. 2015 Jan 5;12(1):232–9.

20. Prabakaran M. Chitosan-based nanoparticles for tumor-targeted drug delivery. *Int J Biol Macromol*. 2015 Jan;72:1313–22.

21. Kudarha R, Dhas NL, Pandey A, Belgamwar VS, Ige PP. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment. *Pharm Dev Technol*. 2015;20(5):608–18.

22. Tupal A, Sabzichi M, Ramezani F, Kouhsoltani M, Hamishehkar H. Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. *J Microencapsul*. 2016 Jun;33(4):372–80.

23. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nat Rev Drug Discov*. 2014 Nov;13(11):813–27.

24. Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. *Biomater Sci*. 2015 Jun 16;3(7):923–36.

25. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. *Pharm Res*. 2011 Feb;28(2):237–59.

26. Vinardell MP, Mitjans M. Antitumor Activities of Metal Oxide Nanoparticles. *Nanomater Basel Switz*. 2015 Jun 9;5(2):1004–21.

References

27. Chaudhari NS, Pandey AP, Patil PO, Tekade AR, Bari SB, Deshmukh PK. Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer. *Mater Sci Eng C Mater Biol Appl*. 2014 Apr 1;37:278–85.
28. Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. *AAPS PharmSciTech*. 2014 Aug;15(4):862–71.
29. Somani S, Dufès C. Applications of dendrimers for brain delivery and cancer therapy. *Nanomed*. 2014 Oct;9(15):2403–14.
30. Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy [Internet]. Vol. 2014, *BioMed Research International*. Hindawi; 2014 [cited 2020 Jun 10]. p. e180549. Available from: <https://www.hindawi.com/journals/bmri/2014/180549/>
31. Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches. *Mater Sci Eng C Mater Biol Appl*. 2017 Dec 1;81:607–26.
32. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. *J Control Release Off J Control Release Soc*. 2012 Jan 30;157(2):168–82.
33. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. *FEBS J*. 2011 May;278(9):1429–43.
34. Osterlin S. On the molecular biology of the vitreous in the aphakic eye. *Acta Ophthalmol (Copenh)*. 1977 Jun;55(3):353–61.
35. Cowman MK, Lee H-G, Schwertfeger KL, McCarthy JB, Turley EA. The Content and Size of Hyaluronan in Biological Fluids and Tissues. *Front Immunol*. 2015;6:261.
36. Tammi R, Agren UM, Tuhkanen AL, Tammi M. Hyaluronan metabolism in skin. *Prog Histochem Cytochem*. 1994;29(2):1–81.
37. Laurent UB, Tengblad A. Determination of hyaluronate in biological samples by a specific radioassay technique. *Anal Biochem*. 1980 Dec;109(2):386–94.
38. Pitarresi G, Craparo EF, Palumbo FS, Carlisi B, Giammona G. Composite Nanoparticles Based on Hyaluronic Acid Chemically Cross-Linked with α,β -Polyaspartylhydrazide. *Biomacromolecules*. 2007 Jun 1;8(6):1890–8.

References

39. Pandey A, Singh K, Patel S, Singh R, Patel K, Sawant K. Hyaluronic acid tethered pH-responsive alloy-drug nanoconjugates for multimodal therapy of glioblastoma: An intranasal route approach. *Mater Sci Eng C Mater Biol Appl*. 2019 May;98:419–36.
40. Zhao L, Liu M, Wang J, Zhai G. Chondroitin sulfate-based nanocarriers for drug/gene delivery. *Carbohydr Polym*. 2015 Nov 20;133:391–9.
41. Sharma L. Osteoarthritis year in review 2015: clinical. *Osteoarthritis Cartilage*. 2016 Jan;24(1):36–48.
42. Rivera F, Bertignone L, Grandi G, Camisassa R, Comaschi G, Trentini D, et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. *J Orthop Traumatol Off J Ital Soc Orthop Traumatol*. 2016 Mar;17(1):27–33.
43. Murai T, Sougawa N, Kawashima H, Yamaguchi K, Miyasaka M. CD44-chondroitin sulfate interactions mediate leukocyte rolling under physiological flow conditions. *Immunol Lett*. 2004 May 15;93(2–3):163–70.
44. Liu M, Du H, Zhai G. Self-assembled nanoparticles based on chondroitin sulfate-deoxycholic acid conjugates for docetaxel delivery: Effect of degree of substitution of deoxycholic acid. *Colloids Surf B Biointerfaces*. 2016 Oct 1;146:235–44.
45. Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, Gu N, et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. *Biomaterials*. 2011 Jan;32(2):495–502.
46. Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). *Sci Rep*. 2017 26;7(1):6602.
47. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. *J Control Release Off J Control Release Soc*. 2009 Feb 20;134(1):55–61.
48. Strickland DK, Gonas SL, Argraves WS. Diverse roles for the LDL receptor family. *Trends Endocrinol Metab TEM*. 2002 Mar;13(2):66–74.
49. Kamali M, Dinarvand R, Maleki H, Arzani H, Mahdavian P, Nekounam H, et al. Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma. *RSC Adv*. 2015 Jul 16;5(76):62214–9.
50. Jain D, Bajaj A, Athawale R, Shrikhande S, Goel PN, Nikam Y, et al. Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential

References

treatment of gliomas: development, characterization and in vivo studies. *Drug Deliv.* 2016;23(3):999–1016.

51. Huang D, Chen Y-S, Rupenthal ID. Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina. *Mol Pharm.* 2017 06;14(2):533–45.

52. Fang C, Wang K, Stephen ZR, Mu Q, Kievit FM, Chiu DT, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. *ACS Appl Mater Interfaces.* 2015 Apr 1;7(12):6674–82.

53. Song Z, Lu Y, Zhang X, Wang H, Han J, Dong C. Novel curcumin-loaded human serum albumin nanoparticles surface functionalized with folate: characterization and in vitro/vivo evaluation. *Drug Des Devel Ther.* 2016;10:2643–9.

54. Katas H, Hussain Z, Awang SA. Bovine Serum Albumin-Loaded Chitosan/Dextran Nanoparticles: Preparation and Evaluation of Ex Vivo Colloidal Stability in Serum [Internet]. Vol. 2013, *Journal of Nanomaterials*. Hindawi; 2013 [cited 2020 Oct 6]. p. e536291. Available from: <https://www.hindawi.com/journals/jnm/2013/536291/>

55. Zhang G-S, Hu P-Y, Li D-X, He M-Z, Rao X-Y, Luo X-J, et al. Formulations, Hemolytic and Pharmacokinetic Studies on Saikosaponin a and Saikosaponin d Compound Liposomes. *Molecules.* 2015 Apr;20(4):5889–907.

56. Yadav AK, Agarwal A, Rai G, Mishra P, Jain S, Mishra AK, et al. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. *Drug Deliv.* 2010 Nov;17(8):561–72.

57. Ananta JS, Paulmurugan R, Massoud TF. Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. *Mol Pharm.* 2015 Dec 7;12(12):4509–17.

58. Su Z, Xing L, Chen Y, Xu Y, Yang F, Zhang C, et al. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. *Mol Pharm.* 2014 Jun 2;11(6):1823–34.

59. Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. *Nat Protoc.* 2007 Feb;2(2):329–33.

60. Khan A, Imam SS, Aqil M, Ahad A, Sultana Y, Ali A, et al. Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. *Mol Pharm.* 2016 07;13(11):3773–82.

References

61. Jain DS, Bajaj AN, Athawale RB, Shikhande SS, Pandey A, Goel PN, et al. Thermosensitive PLA based nanodispersion for targeting brain tumor via intranasal route. *Mater Sci Eng C Mater Biol Appl*. 2016 Jun;63:411–21.
62. Semete B, Booyesen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. *Nanomedicine Nanotechnol Biol Med*. 2010 Oct;6(5):662–71.
63. Xu Y, Shen M, Li Y, Sun Y, Teng Y, Wang Y, et al. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. *Oncotarget*. 2016 Mar 3;7(15):20890–901.
64. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2007 Dec 1;13(23):7101–6.
65. Bharti N, Harikumar SL, Buddiraja A. Development and characterization of albumin nanoparticles for pulmonary drug delivery. :7.
66. Chitkara D, Kumar N. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs. *Pharm Res*. 2013 Sep;30(9):2396–409.